TY - JOUR
T1 - Targeted therapies for cancer 2004
AU - Ross, Jeffrey S.
AU - Schenkein, David P.
AU - Pietrusko, Robert
AU - Rolfe, Mark
AU - Linette, Gerald P.
AU - Stec, James
AU - Stagliano, Nancy E.
AU - Ginsburg, Geoffrey S.
AU - Symmans, W. Fraser
AU - Pusztai, Lajos
AU - Hortobagyi, Gabriel N.
PY - 2004/10
Y1 - 2004/10
N2 - The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)-and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment-are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer. The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.
AB - The regulatory agency approvals in the United States and Europe of imatinib mesylate (Gleevec) for patients with bcr/abl-positive chronic myelogenous leukemia, cetuximab (Erbitux) for patients with epidermal growth factor receptor overexpressing metastatic colorectal cancer, the antiangiogenesis agent bevacizumab (Avastin), and the proteasome inhibitor bortezomib (Velcade)-and the considerable public interest in new anticancer drugs that take advantage of specific genetic defects that render the malignant cells more likely to respond to specific treatment-are driving a new era of integrated diagnostics and therapeutics. The recent discovery of a drug response predicting activating mutation in the epidermal growth factor receptor gene for patients with non-small cell lung cancer treated with gefitinib (Iressa) has intensified this interest. In this review, the history of targeted anticancer therapies is highlighted, with focus on the development of molecular diagnostics for hematologic malignancies and the emergence of trastuzumab (Herceptin), an antibody-based targeted therapy for HER-2/neu overexpressing metastatic breast cancer. The potential of pharmacogenomic strategies and the use of high-density genomic microarrays to classify and select therapy for cancer are briefly considered. This review also considers the widely held view that, in the next 5 to 10 years, the clinical application of molecular diagnostics will further revolutionize the drug discovery and development process; customize the selection, dosing, route of administration of existing and new therapeutic agents; and truly personalize medical care for cancer patients.
KW - Cancer
KW - Molecular diagnostics
KW - Personalized medicine
KW - Review
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=4644245221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644245221&partnerID=8YFLogxK
U2 - 10.1309/5CWPU41AFR1VYM3F
DO - 10.1309/5CWPU41AFR1VYM3F
M3 - Review article
C2 - 15487459
AN - SCOPUS:4644245221
SN - 0002-9173
VL - 122
SP - 598
EP - 609
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 4
ER -